Epigenetics behind tumor immunology: a mini review

Immunogenic- and immune-therapies have become hot spots in the treatment of cancer. Although promising, these strategies are frequently associated with innate or acquired resistance, calling for combined targeting of immune inhibitory signals. Epigenetic therapy is attracting considerable attention as a combination partner for immune-based therapies due to its role in molding the state and fate of cancer and immune cells in the tumor microenvironment. Here, we describe epigenetic dysregulations in cancer, with a particular focus on those related to innate immune signaling and Type I interferons, and emphasize opportunities and current efforts to translate this knowledge into treatment regimens with improved clinical benefit.

Automated summary

Immunogenic- and immune-therapies have become popular for cancer treatment, but resistance is a common challenge. Combining these therapies with epigenetic therapy has shown potential in improving clinical outcomes by targeting immune inhibitory signals. This article focuses on epigenetic dysregulations in cancer, particularly innate immune signaling and Type I interferons, and discusses efforts to translate this knowledge into effective treatment regimens.